Ascentage Pharma Announces First Patient Dosed in Europe in the Phase Ib/II Study of the Bcl-2 inhibitor APG-2575 in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Hopefully the next approval will be for CLL patients, but there is still much work to be done in clinical trials to get us across that finish line.
CAR-T therapy should and will be a significant part of CLL treatment, hopefully in the not too distant future
For now, our friends with a sister B cell lymphoma, Mantle Cell Lymphoma, have reason to celebrate.
Here is the link to FDA’ s official Press Release.
Related posts
